Palatin Technologies plans to move two experimental obesity-targeting therapies into clinical testing for Bardet-Biedl syndrome (BBS) and hypothalamic obesity (HO) over the next two years, with the launch of early trials involving people…

The European Commission (EC) has approved Imcivree (setmelanotide) to treat obesity and control hunger in people ages 4 years or older with acquired hypothalamic obesity (aHO) caused by damage to the brain’s appetite-control…

People with Bardet-Biedl syndrome (BBS) caused by a mutation called p.(Met390Arg) in both copies of the BBS1 gene may develop vision symptoms later and reach major vision loss at older ages than people with…